Document is current

Article History

Received: 17 January 2020

Revised: 19 June 2020

Accepted: 7 September 2020

First Online: 20 September 2020

Compliance with ethical standards

:

: J. C. has received research support from Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer, Jazz Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, ImmunoGen, Merus, and Arog Pharmaceuticals, and acted as a consultant for Bristol-Myers Squibb, Novartis, Pfizer, Jazz Pharmaceuticals, Astellas Pharma, and Daiichi Sankyo. N. P. consulted for and received honoraria from Alexion Pharmaceuticals, Pfizer, CTi BioPharma, Agios Pharmaceuticals, Blueprint Medicines, Incyte, Novartis, and Celgene, received research grants from Celgene, and institution funding for administration of clinical trials from Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Sunesis Pharmaceuticals, Celator Pharmaceuticals, Pfizer, Astex Pharmaceuticals, CTi Biopharma, Genentech, AI Therapeutics, Samus Therapeutics, Arog Pharmaceuticals, and Kartos Therapeutics. H. K. has received research grants from AbbVie, Agios Pharmaceuticals, Amgen, Ariad Pharmaceuticals, Astex Pharmaceuticals, Bristol-Myers Squibb, Cyclacel, Daiichi Sankyo, Immunogen, Jazz Pharmaceuticals, Novartis, Pfizer, and honoraria from AbbVie, Actinium Pharmaceuticals (Advisory Board), Agios Pharmaceuticals, Amgen, Immunogen, Orsinex, Pfizer, and Takeda. A. M. Z. is a Leukemia and Lymphoma Society Scholar in Clinical Research and is also supported by a NCI’s Cancer Clinical Investigator Team Leadership Award (CCITLA). A. M. Z. received research funding (institutional) from Celgene, Acceleron, Abbvie, Otsuka, Pfizer, Medimmune/AstraZeneca, Boehringer Ingelheim, Trovagene, Incyte, Takeda, and ADC Therapeutics. A.M.Z. had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene, Jazz, Ariad, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Seattle Genetics, BeyondSpring, and Takeda. None of these relationships were related to the development of this manuscript. T. T. is an employee of Boehringer Ingelheim International GmbH. N. F. and S. R. are employees of Boehringer Ingelheim Pharmaceuticals, Inc. G. L. U. has received honoraria from Boehringer Ingelheim, Astellas Pharma, and Pfizer. G. B. and M. S. have no conflicts of interest to declare.

: To ensure independent interpretation of clinical study results, Boehringer Ingelheim grants all external authors access to all relevant material, including participant-level clinical study data, and relevant material as needed by them to fulfill their role and obligations as authors under the ICMJE criteria. Furthermore, clinical study documents (e.g. study report, study protocol, statistical analysis plan) and participant clinical study data are available to be shared after publication of the primary manuscript in a peer-reviewed journal and if regulatory activities are complete and other criteria met per the BI Policy on Transparency and Publication of Clinical Study Data:. Prior to providing access, documents will be examined, and, if necessary, redacted and the data will be de-identified, to protect the personal data of study participants and personnel, and to respect the boundaries of the informed consent of the study participants. Clinical Study Reports and Related Clinical Documents can be requested via this link:. All such requests will be governed by a Document Sharing Agreement. Bona fide, qualified scientific and medical researchers may request access to de-identified, analyzable participant clinical study data with corresponding documentation describing the structure and content of the datasets. Upon approval, and governed by a Data Sharing Agreement, data are shared in a secured data-access system for a limited period of 1 year, which may be extended upon request. Researchers should useto request access to study data.